210 related articles for article (PubMed ID: 12121792)
41. Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential.
Thompson KH; Liboiron BD; Sun Y; Bellman KD; Setyawati IA; Patrick BO; Karunaratne V; Rawji G; Wheeler J; Sutton K; Bhanot S; Cassidy C; McNeill JH; Yuen VG; Orvig C
J Biol Inorg Chem; 2003 Jan; 8(1-2):66-74. PubMed ID: 12459900
[TBL] [Abstract][Full Text] [Related]
42. A new orally active antidiabetic vanadyl complex--bis(alpha-furancarboxylato)oxovanadium(IV).
Xie M; Gao L; Li L; Liu W; Yan S
J Inorg Biochem; 2005 Feb; 99(2):546-51. PubMed ID: 15621288
[TBL] [Abstract][Full Text] [Related]
43. Insulin-enhancing activity of a dinuclear vanadium complex: 5-chloro-salicylaldhyde ethylenediamine oxovanadium(V) and its permeability and cytotoxicity.
Xie MJ; Yang XD; Liu WP; Yan SP; Meng ZH
J Inorg Biochem; 2010 Aug; 104(8):851-7. PubMed ID: 20434776
[TBL] [Abstract][Full Text] [Related]
44. Insulin-like effect of vanadyl ion on streptozotocin-induced diabetic rats.
Sakurai H; Tsuchiya K; Nukatsuka M; Sofue M; Kawada J
J Endocrinol; 1990 Sep; 126(3):451-9. PubMed ID: 2170556
[TBL] [Abstract][Full Text] [Related]
45. A family of insulinomimetic zinc(II) complexes of amino ligands with Zn(Nn) (n=3 and 4) coordination modes.
Yoshikawa Y; Kondo M; Sakurai H; Kojima Y
J Inorg Biochem; 2005 Jul; 99(7):1497-503. PubMed ID: 15921760
[TBL] [Abstract][Full Text] [Related]
46. Synthesis, Characterization, and Anti-diabetic Activity of Some Novel Vanadium-Folate-Amino Acid Materials.
Naglah AM; Al-Omar MA; Almehizia AA; Obaidullah AJ; Bhat MA; Kalmouch A; Al-Wasidi AS; Al-Humaidi JY; Refat MS
Biomolecules; 2020 May; 10(5):. PubMed ID: 32443614
[TBL] [Abstract][Full Text] [Related]
47. Antidiabetic zinc(II)-N-acetyl-L-cysteine complex: evaluations of in vitro insulinomimetic and in vivo blood glucose-lowering activities.
Adachi Y; Yoshikawa Y; Sakurai H
Biofactors; 2007; 29(4):213-23. PubMed ID: 18057552
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of insulin-mimetic activities of vanadyl and zinc(II) complexes from the viewpoint of heterocyclic bidentate ligands.
Katoh A; Matsumura Y; Yoshikawa Y; Yasui H; Sakurai H
J Inorg Biochem; 2009 Apr; 103(4):567-74. PubMed ID: 19162327
[TBL] [Abstract][Full Text] [Related]
49. New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals.
Liboiron BD; Thompson KH; Hanson GR; Lam E; Aebischer N; Orvig C
J Am Chem Soc; 2005 Apr; 127(14):5104-15. PubMed ID: 15810845
[TBL] [Abstract][Full Text] [Related]
50. Development of nanofunctionalized oxovanadium(IV) complex and its anticancer, antidiabetic, DNA cleavage and cell imaging studies.
Sunitha N; Isac Sobana Raj C; Sindhu Kumari B
Int J Pharm; 2023 Sep; 644():123339. PubMed ID: 37611853
[TBL] [Abstract][Full Text] [Related]
51. Insulin mimetic effects of macrocyclic binuclear oxovanadium complexes on streptozotocin-induced experimental diabetes in rats.
Ramachandran B; Kandaswamy M; Narayanan V; Subramanian S
Diabetes Obes Metab; 2003 Nov; 5(6):455-61. PubMed ID: 14617232
[TBL] [Abstract][Full Text] [Related]
52. Aminoacid-derivatised picolinato-oxidovanadium(IV) complexes: characterisation, speciation and ex vivo insulin-mimetic potential.
Esbak H; Enyedy EA; Kiss T; Yoshikawa Y; Sakurai H; Garribba E; Rehder D
J Inorg Biochem; 2009 Apr; 103(4):590-600. PubMed ID: 19121544
[TBL] [Abstract][Full Text] [Related]
53. The antilipolytic action of bis(alpha-furancarboxylato)oxovanadium(IV) in adipocytes.
Gao L; Niu Y; Liu W; Xie M; Liu X; Chen Z; Li L
Clin Chim Acta; 2008 Feb; 388(1-2):89-94. PubMed ID: 17991430
[TBL] [Abstract][Full Text] [Related]
54. Synthesis of a vanadyl (IV) folate complex for the treatment of diabetes: spectroscopic, structural, and biological characterization.
Naglah AM; Refat MS; Al-Omar MA; Bhat MA; AlKahtani HM; Al-Wasidi AS
Drug Des Devel Ther; 2019; 13():1409-1420. PubMed ID: 31118576
[TBL] [Abstract][Full Text] [Related]
55. Study of the antidiabetic capacity of the VO(dmpp)2 complex.
Passadouro M; Metelo AM; Melão AS; Pedro JR; Faneca H; Carvalho E; Castro MM
J Inorg Biochem; 2010 Sep; 104(9):987-92. PubMed ID: 20627316
[TBL] [Abstract][Full Text] [Related]
56. [The vanadium compounds: chemistry, synthesis, insulinomimetic properties].
Fedorova EV; Buriakina AV; Vorob'eva NM; Baranova NI
Biomed Khim; 2014; 60(4):416-29. PubMed ID: 25249525
[TBL] [Abstract][Full Text] [Related]
57. Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes.
Thompson KH; Chiles J; Yuen VG; Tse J; McNeill JH; Orvig C
J Inorg Biochem; 2004 May; 98(5):683-90. PubMed ID: 15134913
[TBL] [Abstract][Full Text] [Related]
58. Metallokinetic study of zinc in the blood of normal rats given insulinomimetic zinc(II) complexes and improvement of diabetes mellitus in type 2 diabetic GK rats by their oral administration.
Fugono J; Fujimoto K; Yasui H; Kawabe K; Yoshikawa Y; Kojima Y; Sakurai H
Drug Metab Pharmacokinet; 2002; 17(4):340-7. PubMed ID: 15618684
[TBL] [Abstract][Full Text] [Related]
59. New insulinomimetic zinc(II) complexes of alpha-amino acids and their derivatives with Zn(N2O2) coordination mode.
Yoshikawa Y; Ueda E; Suzuki Y; Yanagihara N; Sakurai H; Kojima Y
Chem Pharm Bull (Tokyo); 2001 May; 49(5):652-4. PubMed ID: 11383627
[TBL] [Abstract][Full Text] [Related]
60. Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats.
Reul BA; Amin SS; Buchet JP; Ongemba LN; Crans DC; Brichard SM
Br J Pharmacol; 1999 Jan; 126(2):467-77. PubMed ID: 10077240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
